Skip to main content
SLAS2024 Main banner
Sartorius Ad
Back

Wyatt McDonnell, PhD (he/him/his)

Infinimmune, California, United States

Long
Dr. Wyatt McDonnell, PhD is Co-Founder, CEO, and Chairman of the Board of Directors at Infinimmune, a biotechnology company advancing truly human therapeutics to treat human disease. Wyatt and his co-founders started Infinimmune after discovering a new lens through which to view human B cells and their antibodies. Previously, Wyatt worked on world-class single cell technologies at 10x Genomics where he was Technical Lead and Developer of Barcode-Enabled Antigen Mapping (BEAM). Wyatt also developed 10x Genomics’ first therapeutic antibodies and core immunology intellectual property behind three commercial products to interrogate the immune repertoire. As a faculty member at Vanderbilt University Medical Center, Wyatt studied the human immune correlates of chronic viral infection and type 2 diabetes using single cell technology and computational approaches and received Young Investigator awards from CROI, the International Workshop on HIV and Aging, and the American Heart Association. He received his PhD and Masters also at Vanderbilt University for his work on the roles of T and B cells in HIV infection, checkpoint inhibitor toxicity, and other immune-mediated diseases. He has co-authored 31 peer-reviewed papers in journals including Nature, Cell, and Nature Medicine, and 19 published patents in relation to immunobiology, genomics, and disease. He has been invited to speak at conferences including PEGS, the Keystone Symposia, the World Vaccine Congress, and PMWC. Wyatt is a one-time National Spelling Bee finalist and can be found playing piano, reading, or exploring the Bay Area culinary scene in his free time.

Disclosure information not submitted.

Presentation(s):